Comparison of Zidovudine Combination and Tenofovir Combination on the Effectiveness of Therapy and Side Effects in Hiv/Aids Patients in Rsal Mintohardjo

Abstract

Objectives: Tenofovir-based therapy is a newly adopted first-line HIV/AIDS therapy regimen in Indonesia that is replacing the stavudine-based regimen. However, zidovudine-based regimens remain the first-line therapy for patients with HIV/AIDS. This study aimed to compare the effectiveness and incidence of adverse effects with hemoglobin (Hb) in both zidovudine-and tenofovir-based regimens in HIV/AIDS patients at Mintohardjo Hospital. Methods:We used a cross-sectional comparative research design. The data analyzed were medical records of all HIV/AIDS patients treated through 2015. Results:The sample included 75 patients in the zidovudine group and 53 patients in the tenofovir group. Wilcoxon signed-rank tests indicated that both combinations of therapy were effective in improving CD4+ cells. Initial CD4+ cell counts ≤ 200 cells/mm 3 were 4.55 times better at increasing CD4+ cell counts when compared with an initial CD4+ > 200 cells/mm 3 . Chi-square results showed that both treatment combinations affected the decrease in Hb. Patients using the zidovudine combination had 4.59 times greater risk for a Hb decrease compared with the tenofovir combination. Conclusions:Zidovudine-and tenofovir-based regimens had similar effectiveness in increasing CD4+ cell counts, but the tendency to cause anemia in tenofovir-based regimens was less than that of the zidovudine-based regimens.

Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling

“…This might be because AZT-3TC-NVP is taken twice per day (drug burden) that results in the patient not taking the drug appropriately and end up with LTFU and also TDF-3TC-EFV is fixed-dose combinations of ART agents which helps to reduce dosing complexity [45]. Tenofovir regimen is claimed to have a better safety profile, even though it may result renal toxicity, compared to zidovudine because of a reduced incidence of anemia and fat redistribution [46][47][48][49][50], so patients with AZT-3TC-NVP may have a loss of hope on the medication if they become ill due to anemia and other complications and finally may be lost from HIV care [32].…”

The THE SPECTRUM OF OPPORTUNISTIC INFECTIONS AND ASSOCIATED FACTORS AMONG PEOPLE LIVING WITH HIV/AIDS ON HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY AT MERPATI CLINIC, BALI, INDONESIA: A RETROSPECTIVE STUDY

“…Pulmonary tuberculosis (47.8%) followed by oral candidiasis (43.9%), and toxoplasmosis (10.3%) were the most frequently observed OIs. Previous studies also reported the most prevalent OIs were pulmonary tuberculosis followed by oral candidiasis [2,12,[17][18][19][20][21]. Oral candidiasis was previously reported as the most prevalent OI fungal in PLWHA due to severe suppression of the immune system [22].…”

Factors Associated With Quality of Life Among People Living With Hiv/Aids on Highly Active Anti Retroviral Therapy: A Cross-Sectional Study

“…People living with HIV/AIDS (PLWHA) often appears with many comorbidities and stigma from their community [2][3][4]. PLWHA must face the disease caused by HIV infection itself or iatrogenic due to the treatment [5]. Hence, HIV/AIDS gives an increasing health burden that causing several socioeconomic problems for the patient, family, community, and government [1][2].…”